



HEALTHCARE

Pharmaceutical Sales Force Effectiveness Strategies

Evaluating evolving sales models & advanced
technology for a customer centric approach

By Dr Ksenija Jakovcic

For more information,
please call Maureen Croce at 866/464-2776
Fax: 781/639-0529
email: mcroce@hcpro.com

Dr Ksenija Jakovcic

Ksenija Jakovcic is Business Development Manager at SanMed, and provides independent consulting services to the pharmaceutical and biotechnology industry. Following her medical practice, Ksenija has worked with international pharmaceutical companies in Austria and the UK around the areas of clinical research and sales & marketing. Ksenija holds an MD from the University of Vienna, Austria and an MBA from the London Business School.

Copyright © 2009 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Pharmaceutical Sales Force Effectiveness Strategies

Executive Summary	9	
The pharmaceutical industry at a crossroads	9	
Sizing and structuring the sales force for strategic advantage	10	
Recruiting, training and motivating an outstanding sales force	11	
Reinventing the pharmaceutical sales model	12	
Utilizing new technologies for sales excellence	13	
Beyond 2010 – The future of pharmaceutical sales	14	
Chapter 1	The pharmaceutical industry at a crossroads	16
Summary		16
Introduction		17
The state of the pharmaceutical industry		18
Patent expiration and generic substitution		18
Pipelines not delivering innovative products		20
Slowing growth in mature markets		23
Government intervention and price controls		25
Poor reputation and new restrictions		26
Restricted access for pharmaceutical sales representatives		27
Pharma industry revises Codes on interactions with physicians		29
The traditional go-to-market strategy		31
ROI in pharmaceutical sales force has plummeted		32
The access problem		34
The end of armies of pharma sales reps in the field		34
Need for new marketing and sales approaches		36

Chapter 2 Sizing and structuring the sales force for strategic advantage 40

Summary	40
Introduction	41
The role of the sales force	41
Determining sales force size	42
Activity-based method	42
Target return-per-call method	43
Sales response method	44
Getting sales force deployment right	45
Resource allocation	45
Optimal profitability	46
Matching sales force structure with companies' business lifecycle	48
Sales force structure	48
Getting the size right	50
From mass market endeavor to individual physicians' needs	51
Rethinking targeting strategy	51
The impact of lifecycle factors on sales force targeting	55
Year 1 – New product launch	55
Year 2 – Accelerate growth	56
Year 3 – Defend and grow	56
Year 8 – Manage the sales decline	58
Conclusion	59

Chapter 3 Recruiting, training & motivating an outstanding sales force 62

Summary	62
Introduction	63
Hiring pharma sales reps: Getting the process right	64
The impact of bad hiring decisions	64
The right recruit	65
Key points to consider when hiring	67
The evolving training needs of the pharma sales force	69
The training dilemma	70
Training for the new environment	72
Changing environment places different demands on sales training	75
Motivating and compensating the sales force	79
Motivation	80
Driving performance through incentive compensation plans	82
Conclusion	83

Chapter 4 Reinventing the pharmaceutical sales model 86

Summary	86
Introduction	87
Sales force model progression	88
Addressing a range of new customers	89
Existing stakeholders are gaining influence	90
The path to key account management	92
Is the pharma sales rep an endangered species?	95
The customer-centric approach: a new model for pharmaceutical sales	95
From mass army to specialty sales force	98
Conclusion	99

Chapter 5 Utilizing new technologies for sales excellence 102

Summary	102
Introduction	103
e-Learning – meeting sales reps training needs	104
Case study – e-Learning as part of AstraZeneca’s sales training strategy	104
e-Detailing	105
Virtual live e-Detailing	106
e-Detailing through a portal for doctors	106
Scripted e-Detailing	106
The benefits of e-Detailing	107
Putting it in practice: The key factors for success	108
From tablet PCs to closed loop marketing	109
Will closed-loop marketing transform the pharma sales process?	111
Common pitfalls on the way to implementing closed-loop marketing	114
How to ensure successful implementation of closed-loop marketing	116
Conclusion	117

Chapter 6 Beyond 2010 - The future of pharmaceutical sales 120

Summary	120
Introduction	121
The sales force of the future: variable in size and structure	121

Will samples need pharmaceutical sales reps?	123
New industry models and their implications for sales force effectiveness	125
Aligning marketing and sales to match the healthcare environment	126
The use of analytics to drive sales force approaches	126
Content-driven interactions between sales reps and customers	126
To what extent will the sales model change in the immediate future?	127
Designing a marketing and sales function that is fit for the future	129

Chapter 7 Appendix 134

Bibliography	134
Index	136

List of Figures

Figure 1.1:	Projected revenue losses (\$bn) due to patent expirations, 2007e-2012p	19
Figure 1.2:	R&D investment (\$bn) in the US, 2004-2007	21
Figure 1.3:	FDA new drug approvals, 2000-2008	22
Figure 1.4:	Global pharma market growth slowdown	24
Figure 1.5:	Survey of US medical practices, February 2009	28
Figure 1.6:	US sales force size - top 30 companies, 1997-2007	32
Figure 1.7:	Pharma sales rep funnel	34
Figure 2.8:	Field force: Sales, cost and profit impact	47
Figure 2.9:	The impact of three different sizing scenarios on company profits	50
Figure 2.10:	Physician segmentation enabling effective targeting	54
Figure 2.11:	Modeling doctors' prescribing behavior	58
Figure 3.12:	The training trade-off	71
Figure 3.13:	Effective sales force training responds to a new selling environment	73
Figure 3.14:	Sales rep characteristics with the most influence on physician satisfaction	74
Figure 3.15:	Implications for future sales force training	76
Figure 4.16:	Sales force restructuring and innovation - State of the industry	89
Figure 4.17:	The expected shift in marketing and sales efforts	91
Figure 4.18:	Implications for pharma companies on the path to KAM	94
Figure 5.19:	e-Detailing as part of the multi-channel approach to CRM	109
Figure 5.20:	CLM feedback loop	112
Figure 5.21:	TGaS survey on CLM implementation among top pharma companies, 2007-2008	114
Figure 6.22:	Sampling trends %, 2008	124
Figure 6.23:	Readiness for new business models in the next two years	128
Figure 6.24:	Future organization of the pharmaceutical marketing and sales function	130

List of Tables

Table 1.1:	Blockbusters going off-patent 2010-2012	20
Table 1.2:	Planned job cuts by big pharmaceutical companies, October 2008	35
Table 2.3:	Target return-per-call method in eight steps by Zoltners & Sinha	44
Table 2.4:	Comparison of sales force sizing methods	45
Table 3.5:	Common pharmaceutical sales force training settings	70
Table 5.6:	How tablet PCs support sales force activities	110
Table 6.7:	New approaches to marketing and sales challenges	127